Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair.

Moriwaki K, Balaji S, McQuade T, Malhotra N, Kang J, Chan FK.

Immunity. 2014 Oct 16;41(4):567-78. doi: 10.1016/j.immuni.2014.09.016.

2.

Inhibitors of TonB function identified by a high-throughput screen for inhibitors of iron acquisition in uropathogenic Escherichia coli CFT073.

Yep A, McQuade T, Kirchhoff P, Larsen M, Mobley HL.

MBio. 2014 Feb 25;5(2):e01089-13. doi: 10.1128/mBio.01089-13.

3.

CYLD deubiquitinates RIP1 in the TNF╬▒-induced necrosome to facilitate kinase activation and programmed necrosis.

Moquin DM, McQuade T, Chan FK.

PLoS One. 2013 Oct 2;8(10):e76841. doi: 10.1371/journal.pone.0076841. eCollection 2013.

4.

Positive and negative phosphorylation regulates RIP1- and RIP3-induced programmed necrosis.

McQuade T, Cho Y, Chan FK.

Biochem J. 2013 Dec 15;456(3):409-15. doi: 10.1042/BJ20130860.

5.

The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis.

Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, Damko E, Moquin D, Walz T, McDermott A, Chan FK, Wu H.

Cell. 2012 Jul 20;150(2):339-50. doi: 10.1016/j.cell.2012.06.019.

6.

RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation.

Cho Y, McQuade T, Zhang H, Zhang J, Chan FK.

PLoS One. 2011;6(8):e23209. doi: 10.1371/journal.pone.0023209. Epub 2011 Aug 10.

7.

Functional complementation between FADD and RIP1 in embryos and lymphocytes.

Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J.

Nature. 2011 Mar 17;471(7338):373-6. doi: 10.1038/nature09878. Epub 2011 Mar 2. Erratum in: Nature. 2012 Mar 22;483(7390):498.

8.

Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374.

Sharmeen L, McQuade T, Heldsinger A, Gogliotti R, Domagala J, Gracheck S.

Antiviral Res. 2001 Feb;49(2):101-14.

PMID:
11248362
9.

2,2'-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations.

Domagala JM, Gogliotti R, Sanchez JP, Stier MA, Musa K, Song Y, Loo J, Reily M, Tummino P, Harvey P, Hupe D, Sharmeen L, Mack D, Scholten J, Saunders J, McQuade T.

Drug Des Discov. 1997 May;15(1):49-61.

PMID:
9332831
10.

The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activities.

Tummino PJ, Harvey PJ, McQuade T, Domagala J, Gogliotti R, Sanchez J, Song Y, Hupe D.

Antimicrob Agents Chemother. 1997 Feb;41(2):394-400.

11.

Compounds that target novel cellular components involved in HIV-1 transcription.

Butera ST, Roberts BD, Critchfield JW, Fang G, McQuade T, Gracheck SJ, Folks TM.

Mol Med. 1995 Nov;1(7):758-67.

Supplemental Content

Loading ...
Support Center